MARCH8 targets TRAIL-R1 at K273 for polyubiquitination, which causes its lysosome-dependent degradation in breast cancer cells, leading to the inhibition of TRAIL-R1-mediated apoptosis signaling (90). Here, TNFRSF10A is linked to breast carcinoma.